CREB as an Important Player in the Decline of Immune System Control of Gut Microbiome Composition

Key Takeaways

• CREB activation suppresses PGRP‑SC2 in aging Drosophila gut
• Reduced PGRP‑SC2 raises microbial load and alters F/B ratio
• Boosting PGRP‑SC2 restores gut homeostasis and extends lifespan
• CREB regulation operates outside canonical Imd/Relish pathway
• Targeting CREB‑PGRP‑SC2 may treat age‑related gut dysbiosis

Pulse Analysis

The gut microbiome undergoes profound compositional shifts as humans age, often marked by a declining Firmicutes to Bacteroidetes ratio and heightened inflammatory tone. These changes are not merely passive consequences of senescence; they reflect a deteriorating capacity of the immune system to regulate microbial populations. Understanding the molecular bridges between immune aging and microbiome dysbiosis is essential for developing interventions that can curb "inflammaging" and its downstream metabolic disorders.

In a recent study, Drosophila researchers identified the cAMP response element‑binding protein (CREB) as a pivotal driver of gut immune decline. Elevated CREB activity, triggered by JNK signaling in older flies, directly represses the expression of the peptidoglycan‑recognition protein SC2 (PGRP‑SC2), an enzyme that degrades bacterial cell‑wall components. Loss of PGRP‑SC2 leads to higher bacterial loads and a disrupted Firmicutes/Bacteroidetes balance, accelerating gut hyperplasia and shortening lifespan. Notably, restoring PGRP‑SC2 levels rescues these phenotypes without engaging the traditional Imd/Relish pathway, highlighting a previously unappreciated immune regulatory circuit.

The translational relevance of these findings lies in the conserved nature of CREB signaling and PGRP family proteins across species. If a similar CREB‑PGRP‑SC2 axis operates in mammals, modulating this pathway could become a strategic avenue to reinforce gut barrier integrity, rebalance microbial communities, and mitigate age‑related systemic inflammation. Future work will need to validate the mechanism in mouse models and explore pharmacologic agents that fine‑tune CREB activity or boost PGRP‑like functions, offering a promising frontier for longevity‑focused therapeutics.